OS Therapies announced that the U.S. Food & Drug Administration has upgraded the company’s meeting status for its lead asset, OST‑HER2, from a Type D biomarker meeting to a Type B pre‑BLA meeting. The change signals a shift from biomarker data discussions to accelerated‑approval deliberations and positions the company to file a Biologics License Application by the end of the first quarter of 2026.
OST‑HER2 is a Listeria‑based immunotherapy designed to treat recurrent pulmonary metastatic osteosarcoma. The company has completed its biomarker analysis and is actively filing patents, underscoring its readiness to submit a full clinical data package. The Type B pre‑BLA meeting is a prerequisite for accelerated approval under the FDA’s program, and the company expects to submit the BLA shortly after the meeting.
The regulatory milestone carries significant business implications. A successful accelerated‑approval pathway could bring the therapy to market faster, while the company’s eligibility for a Priority Review Voucher—estimated at $100–$350 million—provides a potential lifeline to address its liquidity constraints. A comparable PRV sale in February 2026 fetched $205 million, illustrating the market’s appetite for such vouchers.
"We credit FDA with taking decisive action to help advance Accelerated Approval discussions regarding OST‑HER2 for pediatric cancer patients with osteosarcoma. With the biomarker analysis complete, and patent filings in process, we are poised to deliver data to the agency that we believe represents surrogate clinical efficacy sufficient to enable our ongoing BLA submission," said Paul Romness, Chairman and CEO.
OS Therapies has also secured several FDA designations for OST‑HER2, including Orphan Drug, Fast Track, and Rare Pediatric Disease Designation, which provide fee waivers and market exclusivity. The company’s comparative‑oncology approach—leveraging the 96 % genetic homology between human and canine osteosarcoma—has supported its development strategy. A recent $2 million convertible‑note raise extended the company’s runway into 2027, mitigating near‑term liquidity risk while the PRV strategy remains a key financial lever.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.